



 **LUNGSTRONG**
Raising for Research

ANNUAL REPORT

— 2022 —





TO *OUR* SUPPORTERS

Last year we celebrated our 10th year as an organization! When LUNGSTRONG started, the goal was to help fund unrestricted research with the hope that new, more effective treatments would become available for those at risk for the disease, allowing patients to live longer and better.

Over the last decade, progress has been made in lung cancer screening and treatments. Advances in surgery, radiotherapy, and molecular testing have benefited those at risk for lung cancer.

Today, molecular testing helps identify targeted treatments for patients. In 2013, 2 mutations, EGFR & ALK, were generally tested. Today, guidelines have expanded to include at least 6 others. In addition, immunotherapy has become a standard of care for patients that do not have a driver mutation. As of 2020, nearly 20 new agents are available to treat lung cancer patients and because of these new treatments, survival rates also continue to improve.

We are encouraged by the progress made but realize there is still much work to be done to reach our mission of a world where lung cancer is no longer fatal but a treatable disease. With your continued help, we continue to work toward that goal.



Diane Legg

founder/president



our MISSION

to raise funds for innovative lung cancer research so that lung cancer is a treatable disease and no longer fatal



All funds raised go to the lung cancer research programs at **Mass General Cancer Center** and **Dana Farber Cancer Institute**

BOARD OF DIRECTORS

100% volunteer



Diane Legg
president/founder



Jill O'Leary
treasurer

OFFICERS



Beth
Vossler



Careyanne
Davis



Dave
Legg



Jill
Carter



Scott
MacDonald



Lauren
Gonthier



Lily
Hanlon



It has been a privilege to partner with the LUNGSTRONG Team over the past decade, and we are so grateful for their tireless advocacy for lung cancer research and consistent support for our team at MGH. LUNGSTRONG funding has supported a number of research programs within the MGH Center for Thoracic Cancers, including translational efforts to re-biopsy and study lung cancers that have become resistant to targeted therapies and develop cell lines from these biopsies that are used by the Hata Lab to develop next-generation targeted therapies. In addition, LUNGSTRONG funding has made an outsized impact on our group's research by providing flexible seed money for exploring new ideas and launching new research directions at the earliest stage, when traditional funding mechanisms are not yet available. By supporting research at this critical phase, **the return on investment of LUNGSTRONG's support for lung cancer research here at MGH has been truly significant.**

Aaron Hata, MD, PhD
Massachusetts General Hospital



LUNGSTRONG has been a critical partner in our mission to develop transformative therapies for patients with lung cancer in the MGH Cancer Center. With the longstanding and generous support from LUNGSTRONG, we have gained fundamental insights into the biology of lung cancers in response to targeted therapies, developed new strategies to overcome resistance, and we are training the next generation of cancer researchers.



Justin Gainor, MD
Massachusetts General Hospital



IMPACT



Governmental funding sources like the NCI will not fund brand new ideas that have never been tried - they require some preliminary data that the new ideas will work before committing to grant investment. Support from LUNGSTRONG has allowed us to explore a variety of novel approaches and has multiplied into additional multi-year funding from NCI.

Lecia Sequist, MD, MPH
Massachusetts General Hospital

Advances in lung cancer therapies and outcomes come from research. *It is vitally important to continue research and to study why cancers respond, why are they different, why do therapies work, and why do they stop working. For this work, it is important to support early clinical and pre-clinical activity to get new hypothesis out and to ultimately test them in the clinic. This is where LUNGSTRONG support is so critical.*



Päsi Janne, MD, MPH
Dana Farber Cancer Institute

FINANCIALS



\$5,927,273

total given since inception to both MGH and Dana Farber

2022 BREAKDOWN

MGH
\$180,000

Dana Farber
\$428,491



5K

\$92,775

participants

800

volunteers

100



LIVE IT UP

\$20,569

participants

150

volunteers

25



CHEERS FOR A CURE

\$7,381

participants

14

restaurant partners and volunteers

10



PMC

\$428,491

participants

54

volunteers

20



GENERAL DONATION


\$52,025



9

Board Members
all volunteer

FINANCIALS



only 4% expenses!

OUR SPONSORS

5K

BDO
Boston Bruins Foundation
Brookwood Financial Partners
Candel Therapeutics
Goulder Family Foundation
HUB International New England
Judith Antoine Shanley Foundation
Mintz Levin
Morgan, Lewis & Bockius
Newburyport Development
Jack Noonan
Rollins Family Trust
R.W. Hyde Construction, Inc.
Tuscan Brands

Live it Up

Elite Pharmaceuticals, Inc.
Linden Financial Group

10-Year Sponsor

New England Biolabs

PMC

Blue Water Mortgage Corporation
Circle Insurance
Crystal Engineering
REF Haircare
Ristorante Molise
GameTime Lanes & Entertainment
The Hanlon Family
Michael's Harborside
Phat Cats Bistro

Cheers for a Cure

The Barn Pub & Grille
Bean and Cone
Crave
Flatbread
GameTime Lanes & Entertainment
Hodgie's Ice Cream
Market Square Bakehouse
Michael's Harborside
Ristorante Molise
Plum Island Grille
Phat Cats Bistro
Sky-Hi

thanks to our sponsors...

100%

of donations
go to the cause

THANK YOU

to Massachusetts General Hospital,
Dana Farber Cancer Institute, and
their doctors and researchers for their
tireless efforts searching for a cure
for lung cancer



Learn more at
lungstrong.org